Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRVO | CervoMed Inc.

Index	-	P/E	-	EPS (ttm)	-6.41	Insider Own	0.10%	Shs Outstand	5.70M	Perf Week	-5.71%
Market Cap	24.16M	Forward P/E	-	EPS next Y	-5.59	Insider Trans	0.00%	Shs Float	3.30M	Perf Month	-13.81%
Income	-13.10M	PEG	-	EPS next Q	-	Inst Own	9.60%	Short Float / Ratio	1.00% / 0.61	Perf Quarter	-13.24%
Sales	1.41M	P/S	17.16	EPS this Y	38.00%	Inst Trans	-3.65%	Short Interest	0.03M	Perf Half Y	-47.26%
Book/sh	6.97	P/B	0.66	EPS next Y	-	ROA	-63.00%	Target Price	17.00	Perf Year	-45.97%
Cash/sh	2.87	P/C	1.61	EPS next 5Y	-	ROE	-70.00%	52W Range	4.14 - 14.37	Perf YTD	-39.10%
Dividend	-	P/FCF	-	EPS past 5Y	49.10%	ROI	-	52W High	-67.85%	Beta	1.73
Dividend %	-	Quick Ratio	10.70	Sales past 5Y	-	Gross Margin	-	52W Low	11.59%	ATR	0.69
Employees	13	Current Ratio	10.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	41.35	Volatility	13.72% 11.92%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	49.60%	Profit Margin	-	Rel Volume	0.69	Prev Close	4.90
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	54.55K	Price	4.62
Recom	2.00	SMA20	-13.82%	SMA50	-10.73%	SMA200	-32.63%	Volume	37,909	Change	-5.71%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-20	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-21-18	Initiated	H.C. Wainwright	Buy	$1.25

Sep-18-23 10:40AM	CRVO: Publication in Neurology Highlights Correlation Between ptau181 Level and Response to Neflamapimod (Zacks Small Cap Research)
Sep-05-23 07:00AM	CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire) -13.99%
Aug-21-23 08:16AM	CRVO: Initiating Coverage of CervoMed, Inc.; Phase 2b Trial in Dementia with Lewy Bodies Underway (Zacks Small Cap Research)
Aug-15-23 04:01PM	Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma (GlobeNewswire) +7.95%
Mar-30-23 07:00AM	EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases (GlobeNewswire) -12.78%
06:30AM	Loading…
Dec-16-22 06:30AM	Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities (GlobeNewswire)
Dec-05-22 06:30AM	Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeScis History of Stockholder Value Destruction and Self-Dealing (GlobeNewswire) +6.89%
Dec-01-22 07:55AM	DFFN: Strategic Review Underway; Planning to Initiate Phase 2 GBM Trial in 1Q23 (Zacks Small Cap Research) -5.54%
Nov-17-22 05:20PM	LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion Pharmaceuticals (GlobeNewswire)
Nov-14-22 04:01PM	Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.40%
06:30AM	Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process (GlobeNewswire)
Oct-25-22 06:30AM	Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC (GlobeNewswire) +6.22%
Aug-17-22 08:52AM	DFFN: Phase 2 GBM Trial to Initiate 2H22 (Zacks Small Cap Research)
Aug-11-22 06:48PM	Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-26-22 07:30AM	Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation (GlobeNewswire) -7.31%
07:30AM	Loading…
Jun-23-22 07:30AM	Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial (GlobeNewswire) -7.40%
May-20-22 08:10AM	DFFN: Data from Altitude Trial Expected in June 2022 (Zacks Small Cap Research)
May-18-22 07:30AM	Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer (GlobeNewswire) -6.65%
May-17-22 07:30AM	Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 04:05PM	Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.67%
May-04-22 07:20AM	Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements (GlobeNewswire)
Apr-18-22 10:42AM	Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow (Benzinga) -34.22%
09:20AM	Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan (GlobeNewswire)
Apr-11-22 07:20AM	Diffusion Pharmaceuticals Completes Dosing in Altitude Trial (GlobeNewswire)
Apr-08-22 07:20AM	Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders (GlobeNewswire)
Apr-06-22 10:15AM	10 Biotech Penny Stocks with Growth Catalysts (Insider Monkey)
Mar-23-22 10:20AM	DFFN: Additional Tissue Oxygenation Trial Results Expected Mid-2022 (Zacks Small Cap Research) +29.98%
Mar-21-22 07:20AM	Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-09-22 04:56AM	We're Keeping An Eye On Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate (Simply Wall St.) +5.31%
Feb-24-22 07:02AM	Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts (GlobeNewswire)
07:02AM	Loading…
Dec-20-21 07:02AM	Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during J.P. Morgan Week 2022 (GlobeNewswire)
Dec-16-21 08:59AM	Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial (GlobeNewswire)
Dec-01-21 07:02AM	Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523 (GlobeNewswire)
Nov-30-21 11:57AM	10 Biotech Penny Stocks to Buy Now (Insider Monkey) -8.16%
Nov-29-21 06:27AM	DFFN: TSC to be Developed for Treatment of Hypoxic Tumors (Zacks Small Cap Research)
Nov-22-21 07:02AM	Diffusion Pharmaceuticals Doses First Participants in Altitude Trial (GlobeNewswire) -8.51%
Nov-10-21 07:02AM	Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-21 07:30AM	Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference (GlobeNewswire)
Sep-10-21 07:02AM	We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate (Simply Wall St.)
Sep-09-21 07:32AM	Diffusion Pharmaceuticals Issues Letter to Shareholders (GlobeNewswire)
Sep-08-21 07:32AM	Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-30-21 07:32AM	Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDAs Pulmonology, Allergy, and Critical Care Division (GlobeNewswire) +10.20%
Aug-19-21 06:05AM	DFFN: Initial Indication for TSC to be Announced 4Q21 (Zacks Small Cap Research)
Aug-11-21 07:32AM	Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update (GlobeNewswire) -5.27%
Aug-06-21 10:20AM	10 Biotech Penny Stocks to Buy According to Reddit (Insider Monkey)
Jul-06-21 06:34AM	DFFN: TSC Causes Dose Dependent Increase in Tissue Oxygenation in TCOM Trial (Zacks Small Cap Research)
Jun-30-21 11:14AM	Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation (Benzinga)
07:35AM	Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial (GlobeNewswire)
Jun-28-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Jun-21-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021 (GlobeNewswire)
07:35AM	Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum (GlobeNewswire)
Jun-18-21 07:35AM	Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting (GlobeNewswire)
Jun-13-21 06:13PM	Diffusion Pharmaceuticals Inc. (DFFN): Hedge Funds In Wait-and-See Mode (Insider Monkey)
May-14-21 08:21AM	DFFN: Encouraging Data for TSC in COVID-19 Patients (Zacks Small Cap Research)
May-10-21 10:23AM	Diffusion Pharma's Trans Sodium Crocetinate Associated With Improved Outcomes In COVID-19 Patients (Benzinga) +12.85%
07:50AM	Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients (GlobeNewswire)
07:05AM	Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-21 11:47AM	DFFN: Three Studies to Guide Clinical Development of TSC (Zacks Small Cap Research)
11:15AM	DFFN: Three Studies to Guide Clinical Development of TSC (Zacks Small Cap Research)
09:01AM	Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study (GlobeNewswire)
08:45AM	DFFN: Three Studies to Guide Clinical Development of TSC (Zacks Small Cap Research)
Mar-18-21 07:05AM	Diffusion Pharmaceuticals Doses First Participants in TCOM Study (GlobeNewswire)
Mar-17-21 07:05AM	Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update (GlobeNewswire) +5.88%
Mar-14-21 04:47AM	We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate (Simply Wall St.)
Mar-04-21 04:05PM	Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) -12.14%
Feb-18-21 04:05PM	Diffusion Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock (GlobeNewswire)
Feb-17-21 04:13PM	Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock (GlobeNewswire) -12.35%
07:26AM	The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal (Benzinga)
Feb-16-21 09:18AM	Diffusion Pharma Climbs After Completing Early-Stage TSC Study In COVID-19 Patients (Benzinga) +37.10%
07:35AM	Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients (GlobeNewswire)
Feb-11-21 10:02PM	Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million (GlobeNewswire)
05:54PM	Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock (GlobeNewswire)
Jan-11-21 07:30AM	Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference (GlobeNewswire) +34.02%
Dec-04-20 07:20AM	DFFN: Planning for Additional Studies of TSC (Zacks Small Cap Research) +8.30%
Nov-29-20 07:29PM	Is Diffusion Pharmaceuticals Inc. (DFFN) A Good Stock To Buy? (Insider Monkey)
Nov-18-20 11:55AM	Insider Buys Diffusion Pharmaceuticals Shares (Benzinga)
Nov-12-20 04:02PM	Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-19-20 08:00AM	Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer (GlobeNewswire)
Sep-24-20 08:00AM	Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary (GlobeNewswire)
Sep-17-20 03:40PM	DFFN: First Patients Dosed in COVID-19 Trial (Zacks Small Cap Research)
Sep-15-20 07:12AM	We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-11-20 08:30AM	Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference (GlobeNewswire) +7.53%
Sep-10-20 08:00AM	Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial (GlobeNewswire)
Sep-08-20 04:02PM	Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer (GlobeNewswire) -7.53%
Sep-01-20 04:02PM	Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors (GlobeNewswire) -7.10%
Aug-24-20 08:32AM	DFFN: ARDS Trial Set to Get Underway (Zacks Small Cap Research) -6.31%
Aug-10-20 08:00AM	Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-20 08:00AM	Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC (GlobeNewswire) -13.64%
Jul-07-20 08:00AM	Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC (GlobeNewswire)
Jul-06-20 07:47PM	3 Coronavirus Penny Stocks With Triple-Digit Upside Potential (TipRanks)
Jun-11-20 08:00AM	Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of TSC in COVID-19 Patients (GlobeNewswire) -5.56%
Jun-01-20 08:00AM	Diffusion Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement (GlobeNewswire)
May-26-20 08:00AM	Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program (GlobeNewswire)
May-20-20 01:00PM	Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
08:00AM	Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases (GlobeNewswire)
May-19-20 03:18PM	Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example' (Yahoo Finance Video)
09:05AM	DFFN: TSC to be Tested as Treatment for ARDS Caused by COVID-19 (Zacks Small Cap Research)
May-18-20 09:05AM	Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -17.78%
May-11-20 04:11PM	Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) +20.53%
May-05-20 08:00AM	Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS (GlobeNewswire) +11.97%

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRVO | CervoMed Inc.

Upgrade your FINVIZ experience